News

Exelixis has also discussed the trial design with European regulatory agencies. Exelixis is planning to initiate the Phase III trial of XL184 as a potential treatment for medullary

This trial, which is expected to start in July, 2008 is the second Phase I trial for this product. The first Phase I trial was conducted in India,

The results continue to show that romiplostim increased and sustained platelet counts with extended treatment, and reduced the need for concurrent and rescue immune thrombocytopenic purpura (ITP) medications.

In the trial, the currently marketed Azilect 1mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance.

The agreement is subject to certain conditions precedent, including approval by competition authorities in Satisloh’s main host countries. The acquisition could be completed in the second half of

Under the extended agreement, which now runs until June 2010, MorphoSys continues to grant OncoMed access to its proprietary antibody library HuCAL Gold for the use in the

The application seeks approval to initiate Phase I studies on an AMRI compound exclusively licensed to Bristol-Myers Squibb. Upon approval of the clinical trial application by Health Canada,

Results from the first of four treatment groups, involving 12 treated and four placebo patients, demonstrated that the 15mg twice-daily dose of INCB18424 was well tolerated and provided

The new facility provides leading capabilities for the formulation of new investigational medicines that have the potential to treat cancer and other deadly diseases. The center’s technology and